Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Propionate

FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Atopic eczema
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Emphysema
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

    NCT02649478 · start 2014-08

    Registered record
    Registry ID
    NCT02649478
    Conditions
    Asthma
    Interventions
    Fluticasone / Salmeterol; Placebo; Advair Diskus 100/50
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-08
    Completion
    2015-11
    Enrolment
    1,430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone / Salmeterol; Placebo; Advair Diskus 100/50
    PhaseNot applicable
    Registry statusCompleted

  • A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

    NCT02388373 · start 2014-07

    Registered record
    Registry ID
    NCT02388373
    Conditions
    Asthma
    Interventions
    Fluticasone 250/formoterol 10; Fluticasone 250/salmeterol 25; Fluticasone 125/formoterol 5
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-03
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone 250/formoterol 10; Fluticasone 250/salmeterol 25; Fluticasone 125/formoterol 5
    PhasePhase 4
    Registry statusCompleted

  • A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

    NCT02094937 · start 2014-03-27

    Registered record
    Registry ID
    NCT02094937
    Conditions
    Asthma
    Interventions
    Fluticasone Furoate/Vilanterol; Fluticasone Furoate 100 mcg; Fluticasone Propionate 250 mcg; Fluticasone Propionate 100 mcg; Fluticasone Furoate Placebo; Fluticasone Propionate Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-27
    Completion
    2015-08-28
    Enrolment
    430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone Furoate/Vilanterol; Fluticasone Furoate 100 mcg; Fluticasone Propionate 250 mcg; Fluticasone Propionate 100 mcg +2 more
    PhasePhase 3
    Registry statusCompleted

  • Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

    NCT01621321 · start 2013-06

    Registered record
    Registry ID
    NCT01621321
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Prednisolone; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionPrednisolone; Voriconazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps

    NCT01777906 · start 2013-02

    Registered record
    Registry ID
    NCT01777906
    Conditions
    Size of Nasal Polyps; Control of Symptoms
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-02
    Completion
    2017-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSize of Nasal Polyps; Control of Symptoms
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

    NCT01817790 · start 2012-12

    Registered record
    Registry ID
    NCT01817790
    Conditions
    Allergic Rhinitis; Seasonal Allergic Rhinitis
    Interventions
    Fluticasone propionate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-02
    Enrolment
    626

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Seasonal Allergic Rhinitis
    InterventionFluticasone propionate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

    NCT01627327 · start 2012-04-01

    Registered record
    Registry ID
    NCT01627327
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    fluticasone furoate/vilanterol 100/25mcg; tiotropium bromide 18mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04-01
    Completion
    2012-12-21
    Enrolment
    623

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    Interventionfluticasone furoate/vilanterol 100/25mcg; tiotropium bromide 18mcg
    PhasePhase 3
    Registry statusCompleted

  • Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

    NCT01520688 · start 2012-02

    Registered record
    Registry ID
    NCT01520688
    Conditions
    Asthma
    Interventions
    Fluticasone, Budesonide, Beclomethasone; Fluticasone, Beclomethasone, Budesonide; Budesonide, Fluticasone, Beclomethasone; Budesonide, Beclomethasone, Fluticasone; Beclomethasone, Fluticasone, Budesonide; Beclomethasone, Budesonide, Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone, Budesonide, Beclomethasone; Fluticasone, Beclomethasone, Budesonide; Budesonide, Fluticasone, Beclomethasone; Budesonide, Beclomethasone, Fluticasone +2 more
    PhasePhase 4
    Registry statusCompleted

  • Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

    NCT01702701 · start 2012-01

    Registered record
    Registry ID
    NCT01702701
    Conditions
    Eosinophilic Esophagitis; Dysphagia
    Interventions
    Montelukast; Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2017-07-20
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Esophagitis; Dysphagia
    InterventionMontelukast; Fluticasone
    PhasePhase 3
    Registry statusWithdrawn

  • Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

    NCT01436110 · start 2011-09

    Registered record
    Registry ID
    NCT01436110
    Conditions
    Asthma
    Interventions
    Fluticasone furoate 50mcg; Fluticasone propionate 100mcg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-09
    Enrolment
    351

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone furoate 50mcg; Fluticasone propionate 100mcg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

    NCT01395888 · start 2011-06-30

    Registered record
    Registry ID
    NCT01395888
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Tiotropium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-06-30
    Completion
    2012-08-06
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    Interventionfluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Tiotropium
    PhasePhase 3
    Registry statusCompleted

  • Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis

    NCT01321827 · start 2011-04

    Registered record
    Registry ID
    NCT01321827
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Glucocorticoids; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2015-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionGlucocorticoids; Itraconazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

    NCT01313676 · start 2011-01-25

    Registered record
    Registry ID
    NCT01313676
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    fluticasone furoate/vilanterol; fluticasone furoate; vilanterol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-01-25
    Completion
    2015-07-15
    Enrolment
    16,568

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    Interventionfluticasone furoate/vilanterol; fluticasone furoate; vilanterol; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

    NCT01279057 · start 2010-12-27

    Registered record
    Registry ID
    NCT01279057
    Conditions
    Rhinitis, Allergic, Seasonal
    Interventions
    Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals); Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12-27
    Completion
    2011-02-08
    Enrolment
    727

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal
    InterventionFluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals); Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

    NCT01165138 · start 2010-08-20

    Registered record
    Registry ID
    NCT01165138
    Conditions
    Asthma
    Interventions
    Fluticasone furoate/Vilanterol Inhalation Powder; Fluticasone Furoate Inhalation Powder; Placebo Inhaltion Powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08-20
    Completion
    2011-10-19
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone furoate/Vilanterol Inhalation Powder; Fluticasone Furoate Inhalation Powder; Placebo Inhaltion Powder
    PhasePhase 3
    Registry statusCompleted